Movatterモバイル変換

[0]ホーム
URL:

Jump to content
WikipediaThe Free Encyclopedia
Search

AVN-322

From Wikipedia, the free encyclopedia
AVN-322
Names
IUPAC name
5-(benzenesulfonyl)-N,11-dimethyl-2,3,7,11-tetrazatricyclo[7.4.0.02,6]trideca-1(9),3,5,7-tetraen-4-amine;hydrochloride
Other names
List
  • 1194574-68-9
  • SB17475
  • 5-(Benzenesulfonyl)-N,11-dimethyl-2,3,7,11-tetraazatricyclo(7.4.0.0(2,6))trideca-1(9),3,5,7-tetraen-4-amine hydrochloride
  • starbld0039763
[1]
Identifiers
3D model (JSmol)
ChEMBL
ChemSpider
UNII
  • hydrochloride: InChI=1S/C17H19N5O2S.ClH/c1-18-16-15(25(23,24)13-6-4-3-5-7-13)17-19-10-12-11-21(2)9-8-14(12)22(17)20-16;/h3-7,10H,8-9,11H2,1-2H3,(H,18,20);1H
    Key: HLQZXWFRTGIZIJ-UHFFFAOYSA-N
  • free base: InChI=1S/C17H19N5O2S/c1-18-16-15(25(23,24)13-6-4-3-5-7-13)17-19-10-12-11-21(2)9-8-14(12)22(17)20-16/h3-7,10H,8-9,11H2,1-2H3,(H,18,20)
    Key: OSHBEPOEBKFEEK-UHFFFAOYSA-N
  • hydrochloride: CNC1=NN2C3=C(CN(CC3)C)C=NC2=C1S(=O)(=O)C4=CC=CC=C4.Cl
  • free base: CNC1=NN2C3=C(CN(CC3)C)C=NC2=C1S(=O)(=O)C4=CC=CC=C4
Properties
C17H20ClN5O2S
Molar mass393.891 g/mol
Except where otherwise noted, data are given for materials in theirstandard state (at 25 °C [77 °F], 100 kPa).
Chemical compound

AVN-322 is a5-hydroxytryptamine subtype 6 receptorantagonist manufactured by Avineuro Pharmaceuticals Inc. that could potentially be used to combatAlzheimer's disease andschizophrenia.[2][3] AVN-322 also reverses the negative effects ofscopolamine andMK-80.[3]

The compound is asister drug toAVN-101 andAVN-211, two similar compounds under trial for treating Alzheimer's.[3]Phase I trials for the drug were initiated in 2009 by Avineuro, and completed in the spring of 2010.[4][5] The trials showed that AVN-322 was tolerated in a range of doses without any adverse effects, and Avineuro released plans to commencePhase II trials later the same year.[5] The plan for further trials was discontinued in 2013.[6]

References

[edit]
  1. ^National Center for Biotechnology Information. "Compound Summary for CID 135905417, B7DM6S48B2" PubChem. Accessed 12 March 2023.
  2. ^"AVN-322 | CAS#1194574-68-9 | CAS#1194574-33-8 | 5-HT6 Antagonist | MedKoo".www.medkoo.com. Retrieved2023-03-12.
  3. ^abcAndrews, Megan; Tousi, Babak; Sabbagh, Marwan N. (2018-06-01)."5HT6 Antagonists in the Treatment of Alzheimer's Dementia: Current Progress".Neurology and Therapy.7 (1):51–58.doi:10.1007/s40120-018-0095-y.ISSN 2193-6536.PMC 5990506.PMID 29728891.S2CID 19186491.
  4. ^"Avineuro Announces Beginning Of Phase I Clinical Studies Of AVN-322, Potent Small Molecule For Treatment Of Alzheimer's Disease".BioSpace.Archived from the original on 12 Mar 2023. Retrieved2023-03-12.
  5. ^ab"Avineuro Reports Positive Phase I Clinical Trial Results On AVN-322, Potent Small Molecule For Treatment Of Alzheimer's Disease".BioSpace.Archived from the original on 12 Mar 2023. Retrieved2023-03-12.
  6. ^"Phase II trial of AVN 322 in patients with Alzheimer's disease. - AdisInsight".adisinsight.springer.com. Retrieved2023-03-12.
Retrieved from "https://en.wikipedia.org/w/index.php?title=AVN-322&oldid=1307203153"
Categories:
Hidden categories:
[8]ページ先頭
©2009-2025 Movatter.jp